Close Menu

aneuploidy

Under the three-year project award, Premaitha and St George's plan to establish a UK Centre of Excellence for Prenatal Screening.

Vendors and clinicians are struggling with how to deal with the growing number of cases of secondary findings from molecular non-invasive prenatal tests.

While there are already many companies in the space, Agilent believes its relatively quick protocol and higher-throughput capacity will set it apart from competitors' products.

Natera has installed its software on DNAnexus' platform and will use the combined solutions to provide data analysis, storage, and sharing for its genetic tests.

The data demonstrate that the performance of NIPT demonstrated in earlier smaller studies has held true in the context of a dramatically expanded group of clinical samples.

The revenue projection falls short of analyst estimates of $45 million for the quarter and $161 million for the year. 

The companies reached an exclusive deal to provide Natera's Panorama NIPT in the Indian market. 

The company's goal is to transition from a one-test provider to a full-service genetic testing company in the reproductive health and potentially other markets.

The FAST-SeqS test screens embryos for chromosomal aneuploidies prior to implantation in an in vitro fertilization setting. 

Under the agreement, VCGS will develop its own non-invasive prenatal test using Illumina's sequencing technology.

Pages

23andMe has a holiday popup shop at a mall and could open additional stores, Bloomberg reports.

By studying koalas and a retrovirus that infects them, researchers may have uncovered a new sort of 'immune response' that occurs at the genomic level, Agence France Presse reports.

NPR reports that the first person in the US given a gene editing-based therapy for a genetic disorder is heading home.

In Science this week: ancient genomes reveal social inequality within individual households, new method for quantifying genetic variation in gene dosage, and more.